Leap Therapeutics Completes $58.88 Million Cash Private Placement Led by Winklevoss Capital
biotechnology company Leap Therapeutics (NASDAQ stock code: LPTX) announced today that it has completed the previously announced private placement led by Winklevoss Capital, raising $58,888,888 in cash to launch its digital asset financial strategy. Winklevoss Capital will provide funding and strategic support to help Leap build and execute its digital asset financial strategy. Under the lead investor agreement, the Leap board of directors will increase to 12 members, Winklevoss Capital will have the right to nominate two individuals to the Leap board of directors, one of whom will also serve as chairman of the board. Morgan, Lewis & Bockius LLP serves as Leap's legal counsel, and Cooley LLP serves as Winklevoss Capital's legal counsel.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
43 Years of Dividend Growth Keeps XOM Bulls Holding Through the Noise

Chevron Pays $1.78 Dividend Today Backed by 39 Years of Unbroken Growth

Restaurant Brands Is Up 6.7% in 2026 But Reddit Investors Remain Unconvinced
